Patient-Helpdesk.com

alkermes patient assistance program

by Maegan Mann DVM Published 2 years ago Updated 1 year ago

Patient Assistance Programs that help eligible patients with the cost of their prescribed Alkermes medicines. These programs are available for patients in the U.S. who meet insurance coverage and financial criteria, including those who may be facing hardship because of the COVID-19 crisis.

Full Answer

How do I contact Alkermes Patient Assistance Program?

Patient Assistance Program for VIVITROL FAX COVER ALKERMES and VIVITROL are registered trademarks of Alkermes, Inc. Vivitrol2gether is a service mark of Alkermes, Inc. ©2017 Alkermes, Inc. All rights reserved VIV-003438 www.vivitrol.com M-F, 9:00 AM to 8:00 PM ET 1-800-VIVITROL (1-800-848-4876) Fax: 1-800-948-7628

What is Alkermes’ offer policy?

Alkermes reserves the right to rescind, revoke, or amend this offer, program eligibility, and requirements at any time without notice. This offer is limited to one per patient, may not be used with any other offer, is not transferable and may not be sold, purchased or traded, or offered for sale, purchase or trade.

How many nonprofit organizations received Alkermes inspiration grants in 2019?

Eleven U.S. nonprofit organizations received grants from the Alkermes Inspiration Grants program in its fifth installment.

What is it like to work at Alkermes?

Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.

See more

Featured News

February 16, 2022 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022

Responsibility

We champion an approach that views patients holistically and with compassion. Working together with stakeholders across the healthcare community, our team is focused on cutting-edge science, developing innovative medicines and patient-focused advocacy to make a real-world impact in the lives of people living with difficult-to-treat conditions.

Driven by Passion

Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.

COVID-19 Response

In response to urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our medicines and development products.

How often is Aristada administered?

ARISTADA INITIO is intended for single administration in contrast to ARISTADA which is administered monthly, every 6 weeks, or every 8 weeks. Do not substitute ARISTADA INITIO for ARISTADA because of differing pharmacokinetic profiles.

How long is the ARISTADA program?

The ARISTADA Patient Assistance Program provides your uninsured or “functionally” uninsured patients, who meet program eligibility criteria, access to treatment at no charge, for up to 6 months. † Please download and review the enrollment form for complete program information.

Can a healthcare provider enroll a patient in ARISTADA?

The healthcare provider can also initiate enrollment by enrolling the patient in ARISTADA Care Support.

Can Alkermes rescind a program?

This offer is not conditioned on any past, present, or future purchase, including refills. Alkermes reserves the right to res cind, revoke, or amend this offer, program eligibility, and requirements at any time without notice.

Is Aristada safe for elderly?

ARISTADA is indicated for the treatment of schizophrenia in adults. IMPORTANT SAFETY INFORMATION. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 1 2 3 4 5 6 7 8 9